Combination of prostate imaging reporting and data system ( <scp>PI</scp> ‐ <scp>RADS</scp> ) score and prostate‐specific antigen ( <scp>PSA</scp> ) density predicts biopsy outcome in prostate biopsy naïve patients

Abstract

A combination of PI-RADS v2 score and PSA density can help in the decision-making process before prostate biopsy and in the follow-up strategy in biopsy naïve patients. Patients with a PI-RADS v2 score of ≤3 and PSA density of <0.15 ng/mL/mL may avoid unnecessary biopsies.